ArticleInternational dental journal2026
FBXO5 alleviates apical periodontitis by facilitating TP53 protein degradation.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcriptomic Analysis Reveals PACS1 as a Potential Shared Candidate Biomarker for Apical Periodontitis and Osteoporosis.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApical periodontitis (AP) is a common inflammatory disease that irreversibly damages apical papilla tissue and hinders dental regeneration. The molecular mechanisms underlying F-box protein 5 (FBXO5)- and tumor protein p53 (TP53)-mediated regulation of osteogenic differentiation in human stem cells from the apical papilla (hSCAPs) remain to be fully elucidated, particularly in the context of AP pathogenesis.
methodsDifferentially expressed genes in the AP tissues from AP patients and normal controls were identified through bioinformatics analysis. The hSCAPs were isolated from the third molars of healthy human individuals. Alkaline phosphatase (ALP) staining and ALP activity assay, along with Alizarin Red S (ARS) staining, were performed to assess osteogenic differentiation. Stem cell characteristics were identified by flow cytometry. The mRNA and protein expression levels were evaluated by RT-qPCR and Western blotting, respectively. Cell viability and proliferation were assessed using cell counting kit-8 (CCK-8) and 5-ethynyl-2'-deoxyuridine (EdU) assays. The interaction between FBXO5 and TP53 was analyzed by co-immunoprecipitation (Co-IP), cycloheximide (CHX) chase and protein ubiquitination assays.
resultsFBXO5 expression was downregulated in AP tissues. FBXO5 knockdown reduced hSCAPs proliferation and impaired their osteogenic differentiation. Mechanistically, FBXO5 facilitated TP53 ubiquitination-mediated degradation, enhanced hSCAP proliferation by downregulating TP53, and promoted osteogenic differentiation by negatively regulating TP53, showing its key role in maintaining stem cell function during AP progression.
conclusionFBXO5 promoted TP53 degradation to regulate osteogenic differentiation in hSCAPs, which contributed to AP progression. Targeting FBXO5 may provide a potential therapeutic strategy for AP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.